News
NanoString to Release Fourth Quarter and Fiscal Year 2022 Operating Results and Host Conference Call on Tuesday, February 28, 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report fourth quarter and
EQS-Adhoc: Elanix Biotechnologies AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2022 results on Monday, February 27, 2023, after the close of the market. Acadia
Humana Foundation Announces New Strategy to Eliminate Barriers to Equitable Health and Healthcare
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a new strategy to advance health equity by eliminating unjust and unnecessary barriers in
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022.
Fourth Quarter 2022 Financial Highlights:
-
Revenue grew 17%
Chemed To Report Fourth-Quarter 2022 Earnings February 23, Related Conference Call To Be Held On February 24
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2022, on Thursday, February 23, 2023, following the close of trading
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Andy Schmeltz, SVP Commercial Strategy & Innovation, and Navin Katyal, U.S. Commercial &
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
Agilent Technologies Inc. (NYSE: A) today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. The compliance-enabling
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Humana and ChenMed Announce Five-Year Network Agreement
ChenMed, one of the largest senior-focused primary care providers in the United States, and leading health and well-being company Humana Inc. (NYSE: HUM) have signed a new five-year agreement
Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders’ Meeting
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Relief Therapeutics Provides an Update on its Financing Strategy
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 6, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement